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Edited by Vladimir SkulachevAbstract We studied the regulation of glucose-6-phosphate
dehydrogenase (G6PD) gene expression by chronic hypoxia.
G6PD mRNA level and activity were increased in PC12 cells by
hypoxia in a dose- and time-dependent manner. Cobalt chloride
and dimethyloxalylglycine, which can mimic hypoxia, also
activated G6PD gene expression. Interestingly, hypoxia-induced
G6PD expression followed a time course much slower than that
of phosphoglycerate kinase 1 (PGK1), a hypoxia-inducible
factor (HIF)-dependent glycolytic enzyme. Hypoxic-G6PD
induction was almost negligible in non-excitable Buﬀalo rat
liver cells, although in these cells PGK1 was strongly upregu-
lated by low PO2. Furthermore, G6PD but not PGK1 induction
was blocked by the antioxidants glutathione and N-acetylcyste-
ine. These results suggest the dependence of G6PD gene
expression on HIF and intracellular redox status and the
diﬀerential hypoxic regulation of glucose-metabolizing enzymes.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Glucose-6-phosphate dehydrogenase;
Phosphoglycerate kinase 1; Chronic hypoxia;
Hypoxia-inducible factor; Glutathione1. Introduction
Exposure of eukaryotic cells to chronic hypoxia stimulates
the expression of glucose transporters and enzymes that ac-
celerate glucose utilization to compensate for the reduced ac-
tivity of the mitochondrial electron transport chain [1]. The
shift from aerobic respiration to glycolysis is essential for cell
survival in hypoxic conditions, since it provides suﬃcient ATP
to maintain the energy-dependent cellular functions. Some of
the glycolytic enzymes upregulated by hypoxia are phospho-
glycerate kinase (PGK1), aldolase A, pyruvate kinase M, and
6-phosphofructo-2-kinase [1–3]. Chronic hypoxia induces gene
expression through activation of the transcriptional activator
hypoxia-inducible factor 1 (HIF-1) and isoforms. HIF-1 is a* Corresponding author. Fax: +34-954-617301.
E-mail address: jose.l.barneo.sspa@juntadeandalucia.es
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Abbreviations: BRL, Buﬀalo rat liver; CoCl2, cobalt chloride; DMEM,
Dulbecco’s modiﬁed Eagle’s medium; DMOG, dimethyloxalylglycine;
G6PD, glucose-6-phosphate dehydrogenase; GSH, glutathione; HIF,
hypoxia-inducible factor; NAC, N -acetylcysteine; PGK1, phospho-
glycerate kinase 1; PO2, O2 tension; RNS, reactive nitrogen species;
ROS, reactive oxygen species; S.E.M., standard error of the mean; TH,
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1b is constitutively expressed, the level of HIF-1a increases
dramatically at low oxygen tension. Although the level of re-
active oxygen species (ROS) can modulate HIF-1a activity and
thus contribute to chronic oxygen sensing [4,5], recent work
has demonstrated that the regulation of HIF-1a by hypoxia
mainly depends on O2-sensitive prolyl hydroxylases [6,7]. In
normoxia, hydroxylation of a speciﬁc proline residue of the
HIF-1a molecule facilitates its rapid ubiquitylation and deg-
radation by the proteasome. During hypoxia, this degradation
pathway is greatly suppressed, thus resulting in stabilization of
HIF-1a, its translocation to the nucleus, and upregulation of
the HIF-dependent gene expression.
Activation of glycolysis by hypoxia must be coordinated
with other metabolic pathways that also use glucose. Glucose-
6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme
in the pentose phosphate pathway, is necessary for the syn-
thesis of pentoses. G6PD is also involved in antioxidant de-
fense by providing NADPH, a major intracellular reductant.
NADPH is a cofactor in the glutathione (GSH) reductase-
catalyzed reaction to regenerate antioxidant GSH and it is also
required in maintaining the antioxidant enzyme catalase in its
active form. Mouse embryonic stem cells with deleted G6PD
gene fail to induce NADPH production in response to oxi-
dative stress, and this results in decreased GSH/GSH disulﬁde
ratio and cell death [8]. Even mild G6PD deﬁciency produces a
distortion of redox control and oxidative mutagenesis in
mouse brain [9]. On the other hand, overexpression of G6PD
suppresses hydrogen peroxide-induced cell death and the
protection is mediated through the induction of GSH pro-
duction [10,11]. Previous studies have found that G6PD gene
expression is regulated by intracellular redox status. ROS/re-
active nitrogen species (RNS), such as hydrogen peroxide and
peroxynitrite, activate G6PD as part of a cellular response
against oxidative damage [12,13]. On the contrary, the regu-
lation of G6PD gene expression by low oxygen tension is still
not clear and controversial. Anoxia triggers an elevation of
G6PD activity in the brain of gold ﬁsh [14]. Intermittent hy-
poxia increases G6PD activity in the right but not in the left
ventricle in rat [15]. Chronic hypoxia has been found to either
have no eﬀect on G6PD activity in rat intestine and mouse
lung [16,17], or cause a decrease in rat liver [18].
Therefore, in the present study it was investigated whether
chronic hypoxia can regulate G6PD gene expression. It was
also examined if G6PD, an enzyme metabolizing glucose
through a non-energy-producing pathway (pentose phosphate
pathway), was controlled by changes in O2 tension (PO2) in theblished by Elsevier B.V. All rights reserved.
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chromocytoma PC12 cells, a classic O2-sensitive excitable cell
[19,20], that G6PD gene expression and activity are induced by
chronic hypoxia in a dose- and time-dependent manner.
However, this regulation has a diﬀerent time course than that of
PGK1, a well-studied HIF-dependent glycolytic enzyme. In-
terestingly, hypoxia strongly upregulates PGK1 gene induction
in non-excitable Buﬀalo rat liver (BRL) cells but has almost no
eﬀect on the G6PD gene. Hypoxic induction of G6PD in PC12
cells seems to be mediated by ROS, whereas PGK1 induction is
ROS-independent. These results demonstrate that cellular
adaptive responses (anaerobic ATP production and antioxi-
dant defense) against damage caused by changes in PO2 vary in
distinct cell types and are dependent on the diﬀerential hypoxic
regulation of glucose-metabolizing enzymes.2. Materials and methods
2.1. Cell culture and treatments
Rat pheochromocytoma PC12 cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 5% fetal bovine
serum, 10% horse serum, and 1% penicillin/streptomycin. Cells were
routinely cultured with 10% CO2 and ambient air (normoxia, 21% O2)
at 37 C. BRL cells were cultured in DMEM with 10% fetal bovine
serum and 1% penicillin/streptomycin. In these cells, the normoxic
environment had 21% O2 and 5% CO2. For hypoxic treatments, cells
were incubated for variable periods of time in a hypoxic incubator
(ThermoForma, Marietta, OH), where diﬀerent levels of oxygen were
achieved by balancing ambient air with nitrogen. A batch of cells,
maintained during the same time periods in normoxia, were used as
control in all cases. Some cells were treated with either 2 mM GSH
ethyl ester or 2 mM N-acetylcysteine (NAC) during the hypoxic
treatments. To mimic the hypoxic eﬀect, cells maintained in normoxic
PO2 were treated with either 100 lM cobalt chloride (CoCl2), a sta-
bilizer of HIF [21], or 1 mM dimethyloxalylglycine (DMOG), a com-
petitive inhibitor of prolyl hydroxylases [6].
2.2. Analysis of glucose-6-phosphate dehydrogenase activity
Cells were homogenized in extraction buﬀer containing 20 mM Tris–
HCl, 1 mM EDTA, 3 mM MgCl2, 1 mM e-amino-n-caproic acid, and
0.02% (w/v) b-mercaptoethanol, pH 8.0. After centrifugation, the su-
pernatant was collected to measure G6PD activity. G6PD activity was
determined by measuring the rate of NADPH production spectro-
photometrically, as previously described [22]. The activity was then
normalized to the amount of protein determined with the Bradford
method (BioRad Protein Assay, BioRad).
2.3. RNA isolation and Northern blot analysis
Total RNAwas isolated from either PC12 or BRL cells by themethod
of Cathala et al. [23]. Equal amount of RNA (10 g) from each sample
was used to perform theNorthern blot analysis. [32P]UTP-labeled RNA
antisense probes were generated from the following linearized tem-
plates: pCRII-G6PD (G6PD), pCRII-TH (tyrosine hydroxylase (TH)),
and p1B15 (cyclophilin). RNA probes were transcribed with either T7
(pCRII-G6PD and pCRII-TH) or SP6 (p1B15) RNA polymerases.
PGK1 DNA probe was generated by reverse transcription and PCR
ampliﬁcation followed by labeling with [32P]dCTP. The primers used to
amplify the PGK1 fragment were: forward 50-GGC TGG ATG GGC
TTGGAC TG-30 and reverse 50-ATC AACCTC CCAAACCTACA-
30. Blots were hybridized with each probe and the radioactive bands
were visualized by autoradiography.
2.4. Reverse transcription and real-time quantitative PCR
The ﬁrst-strand cDNA was synthesized from 3 lg of total RNA
using the SuperscriptTM ﬁrst-strand cDNA synthesis system with
random primers according to the manufacturer’s instruction (Invitro-
gen). Real-time quantitative PCR was performed in an ABI Prism 7000
Sequence Detection System using SYBR Green PCR Master Mix and
the thermocycler conditions recommended by the manufacturer (Ap-
plied-Biosystems). PCRs were performed in duplicates in a total vol-ume of 30 ll containing 0.2 ll of the reverse transcription reaction
mixture. Primers used to amplify a fragment of each gene were: G6PF1
(50-GCC TTC TAC CCG AAG ACA CCT T-30) and G6PR1 (50-CTG
TTT GCG GAT GTC ATC CA-30) for G6PD, LG9 (50-GCA CTG
GTG GCA AGT CCA T-30) and LG10 (50-GCC AGG ACC TGT
ATG CTT CAG-30) for cyclophilin, LG31 (50-TCG GAA GCT GAT
TGC AGA GA-30) and LG32 (50-TTC CGC TGT GTA TTC CAC
ATG-30) for TH, and LG33 (50-AGAGCC CAC AGT TCC ATGGT-
30) and LG34 (50-GCA AAG TAG TTC AGC TCC TTC TTC A-30)
for PGK1. Each sample was normalized with cyclophilin to perform
the relative quantiﬁcation. Dissociation curve analysis showed a single
sharp peak with the expected melting temperature for all samples.
2.5. Statistical analysis
Data were presented as means standard error of the mean
(S.E.M.), and were analyzed with either Student’s t-test or one-way
analysis of variance followed by Tukey test. P < 0:05 was considered
statistically signiﬁcant.3. Results
3.1. Diﬀerential time-dependent induction of G6PD and PGK1
genes by hypoxia
PC12 cells were treated with chronic hypoxia (3% O2) for up
to 72 h. The mRNA levels of TH, a classic hypoxia-inducible
gene [19], as well as of PGK1 and G6PD increased upon
treatment, as determined by Northern blot analysis and real-
time quantitative PCR (Fig. 1, panels A and B, respectively). A
rapid elevation in mRNA levels of TH and PGK1 (about 2.5-
fold, P < 0:05) was observed after 7 and 24 h of treatments,
respectively, and this increase was maintained for 72 h, as
examined in the present study. G6PD mRNA level also in-
creased in hypoxia, although it was not appreciable until 48 h
of treatment and only reached a 2-fold induction at 72 h
(Fig. 1, panels A and B). Therefore, chronic hypoxia-induced
G6PD gene expression at the transcript level but the eﬀect was
slower than that for TH and PGK1.
To determine the dose dependence of G6PD gene induction
by chronic hypoxia, PC12 cells were incubated at diﬀerent
levels of oxygen and the mRNA was collected after 72 h of
treatment. 10% O2 caused a moderate but signiﬁcant increase
in G6PD mRNA level (1.5-fold) and the increase was en-
hanced to a maximum of about 2-fold with the treatment of
3% O2 (Fig. 1, panel C). 1% O2, tested in only one experiment,
caused a similar induction as 3% O2. These results indicated
that even mild hypoxia could activate G6PD gene expression
and that the induction was dose-dependent. The TH and
PGK1 gene induction followed the same pattern as G6PD in
term of dose, although the level of increase was higher than for
G6PD (data not shown).
The enzymatic activity of G6PD was then measured to as-
sess whether the increase in G6PD transcript upon chronic
hypoxic treatment resulted in an enhancement of its physio-
logical function. Indeed, 3% O2 caused a 30% and 50% in-
crease in G6PD activity after 48 and 72 h of treatments,
respectively (P < 0:05, Fig. 1, panel D). This increase in ac-
tivity followed the same time course as mRNA induction (see
Fig. 1, panel B). Therefore, these results demonstrated that
chronic hypoxia-induced G6PD gene expression in PC12 cells,
which resulted in an increase in its functional activity.
As chronic hypoxia has been shown to have variable eﬀects
on G6PD activity in diﬀerent tissues [16–18], we examined
whether the G6PD upregulation described above was also
present in BRL cells, used as an example of non-excitable cells.
Fig. 1. Diﬀerential time-dependent induction of G6PD and PGK1 genes by chronic hypoxia in PC12 cells. Total RNA and protein were isolated from
PC12 cells treated with 3% O2 for diﬀerent periods of time. A batch of cells, maintained during the same time periods in normoxia, were used as
control (c) in all cases. The mRNA level of each gene was determined by Northern blot analysis (panel A) and real-time quantitative PCR analysis
(panel B). (C) PC12 cells treated with diﬀerent levels of oxygen for 72 h followed by RNA isolation and real-time quantitative PCR. (D) G6PD
activity in cells treated with 3% O2 for diﬀerent periods of time. Data are presented as means S.E.M. from at least four independent experiments. In
the case of G6PD, statistically signiﬁcant values (P < 0:05) are indicated by asterisks.
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O2) for up to 72 h demonstrated a fast, time-dependent, up-
regulation of PGK1 mRNA. Although the hypoxic induction
of PGK1 in BRL cells (about 6-fold after 24 h; Fig. 2, panel A)
was much more potent than in PC12 cells (see Fig. 1, panel B),
lowering PO2 had almost no eﬀect on either G6PDmRNA level
(Fig. 2, panel A) or activity (Fig. 2, panel B). These data indi-
cate that quantitatively the diﬀerential regulation of G6PD and
PGK1 by hypoxia can change among the various cell types.3.2. G6PD is induced by the hypoxia mimics CoCl2 and DMOG
It was further investigated whether G6PD gene expression in
PC12 cells is upregulated by CoCl2 and the membrane-perme-
able prolyl hydroxylase inhibitor DMOG. These compounds
have been used to mimic the HIF-dependent hypoxic eﬀect un-
der normoxic conditions [6,21,24]. As shown in Fig. 3, both
compounds caused a 2-fold increase in mRNA (panel A) and a
70–80% elevation in G6PD activity (panel B) after 72 h of
treatments, which was similar to the eﬀect caused by 3% O2 (see
Fig. 1). These hypoxiamimics inducedG6PDwith a time course
similar to that of low PO2. An iron chelator desferrioxamine,
which has also been used to mimic the HIF-dependent hypoxic
eﬀect [6,24], had a smaller eﬀect on the G6PD mRNA level but
also caused a 50% increase in G6PD activity (data not shown).
Therefore, these data suggested that the hypoxia-inducedG6PD
gene expression was mediated, at least in part, by HIF.
Fig. 2. Diﬀerential induction of PGK1 and G6PD genes by chronic
hypoxia in BRL cells. Total RNA and protein were isolated from BRL
cells treated with 3% O2 for diﬀerent periods of time. The mRNA level
of each gene was determined by real-time quantitative PCR analysis
(panel A). (B) G6PD activity in cells treated with 3% O2 for diﬀerent
periods of time. Data are presented as means S.E.M. from at least
four independent experiments. Statistically signiﬁcant values
(P < 0:05) are indicated by asterisks.3.3. Diﬀerential eﬀect of intracellular redox buﬀers on the
hypoxic regulation of the G6PD and PGK1 genes
ROS have been suggested to be involved in the cellular re-
sponse to hypoxia [4,5]. Therefore, it was examined whether
the G6PD induction was mediated by changes in intracellular
Fig. 3. CoCl2 and DMOG mimicked the hypoxic eﬀect on G6PD in-
duction. PC12 cells were treated with 100 lM CoCl2 or 1 mM DMOG
for 72 h under normoxia. The mRNA level of G6PD was measured by
real-time quantitative PCR (panel A) and the enzymatic activity was
determined spectrophotometrically (panel B). Data were presented as
meansS.E.M. from at least three independent experiments.
*P < 0:05 compared to control.
Fig. 4. Diﬀerential eﬀect of intracellular redox buﬀers on the hypoxic
regulation of the G6PD and PGK1 genes. PC12 cells were treated with
2 mM GSH ethyl ester followed by immediate treatment of 3% O2 for
24 or 72 h, or 100 lM CoCl2 for 72 h. Total RNA was isolated and
the mRNA levels of G6PD (panel A) and PGK1 (panel B) were de-
termined by real-time quantitative PCR. Data were presented as
meansS.E.M. (n ¼ 4). *P < 0:05 compared to control.
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GSH donor, was used to inhibit oxidative stress. As shown in
Fig. 4, GSH ethyl ester itself had no eﬀect on the mRNA levels
of G6PD and PGK1 in PC12 cells under normoxic condition
(21% O2). However, the increase in G6PD transcript, which
was induced by 3% O2 for 72 h, was inhibited almost com-
pletely by 2 mM GSH ethyl ester (Fig. 4, panel A). GSH ethyl
ester was unable to prevent G6PD induction by cobalt (Fig. 4,
panel A) or to suppress the PGK1 induction after either 24 or
72 h of hypoxic treatment (Fig. 4, panel B). Qualitatively,
similar eﬀects were seen with NAC, another widely used an-
tioxidant. At 2 mM, NAC completely suppressed hypoxia-
induced G6PD gene expression in PC12 cells but was without
eﬀect on PGK1 induction (n ¼ 4 experiments). These data
indicated that buﬀering of ROS production with GSH ethyl
ester had no eﬀect on cobalt-induced G6PD gene induction.
Whereas the hypoxia-induced G6PD gene expression was
ROS-dependent, the hypoxic PGK1 induction was not.
4. Discussion
In the present study, we have shown that chronic hypoxia
can induce G6PD gene expression and functional activity in
PC12 cells, a classic excitable O2-sensitive cell type [19,20]. In
addition, we report that the hypoxic induction of G6PD
diﬀers with respect to that of PGK1, another glucose-
metabolizing enzyme, in terms of time course and dependence
on oxidation. In the case of PGK1, which is a typical HIF-inducible enzyme [1,3], the hypoxic induction occurred within
a few hours and was independent of ROS production. On the
other hand, the induction of G6PD occurred relatively late
and the antioxidants GSH or NAC completely abolished the
eﬀect. Induction of PGK1 gene by low PO2 was also ob-
served even with higher potency in non-excitable BRL cells,
although in this preparation the eﬀect of hypoxia on G6PD
was almost negligible.
Although HIF-dependent induction of gene expression by
chronic hypoxia is maintained in the absence of a functional
mitochondrial electron transport chain [25], numerous studies
have suggested that an elevation of ROS production, such as
mitochondria-derived superoxide and subsequently hydrogen
peroxide, can inﬂuence HIF-1 activation in hypoxia-induced
gene expression [4,26–30]. Indeed, it has been reported that
HIF-1 can be activated by changes in intracellular redox sta-
tus. Buthionine-sulfoximine, nitrofurantoin, and phorone,
which can induce oxidative stress, have been reported to
increase HIF-1 protein in the nuclear extracts of rat liver [31],
260 L. Gao et al. / FEBS Letters 569 (2004) 256–260and pretreatment with arsenite, which can induce ROS pro-
duction, results in accumulation of HIF-1a protein and in-
duction of the vascular endothelial growth factor gene [32].
Reducing agents, such as GSH and NAC, block hypoxia-
induced PC12 cell death [33]; however, a decrease of ROS
production during hypoxia-induced erythropoietin gene ex-
pression has also been reported [34].
Our results support the view that induction by hypoxia of
some HIF-dependent genes, i.e., PGK1, appears to be com-
pletely independent of ROS formation in excitable PC12 cells,
whereas in other genes, as in the case of G6PD, hypoxic regu-
lation depends both on HIF and ROS accumulation. We have
observed clear diﬀerences in the potency of hypoxia to induce
G6PD in PC12 and BRL cells, which could be due to a higher
production of ROS in response to hypoxia in excitable (PC12)
cells. The involvement of HIF in hypoxic G6PD-induction is
suggested because the same increase of G6PD mRNA is pro-
duced in normoxic conditions and independently of ROS by
CoCl2 and DMOG (Figs. 3 and 4). In fact, there is a putative
HIF-1 binding site (TACGTG) [24,35] located in the promoter
region of rat G6PD gene, which is about 290 bases upstream of
the transcription initiation site (GenBank Accession No.
X69768). Desferrioxamine, an iron chelator that also mimics
the HIF-dependent hypoxic eﬀect [6,24], induced a smaller in-
crease of G6PD mRNA than CoCl2 or DMOG. Nevertheless,
this result is expected since desferrioxamine activates HIF and
mimics hypoxia but also diminishes the iron-dependent ROS
formation [36] and thus reduces G6PD expression.
In conclusion, our data show that glucose-metabolizing en-
zymes are regulated diﬀerentially by hypoxia through separate
mechanisms. Fast hypoxic induction is observed for PGK1, a
gene highly sensitive to HIF activation. In contrast, a much
slower induction is produced in the case of G6PD, possibly
because it is less sensitive to HIF, and more importantly, re-
quires ROS accumulation and a prolonged exposure to low
PO2. The regulation of glycolytic enzymes (PGK1 among
others) and G6PD by hypoxia with diﬀerent time courses
could have an important adaptive role for cell survival. In the
early stages of hypoxia, prior to the accumulation of ROS,
induction of glycolytic enzymes is surely of critical need to
accelerate the anaerobic synthesis of ATP. During long hyp-
oxic exposures, however, the antioxidant and protective eﬀect
of G6PD due to NADPH synthesis [10,11] could be more
necessary to avoid ROS accumulation and cell death. There
are diﬀerences in the potency of hypoxia to induce G6PD in
PC12 and BRL cells, which could be a consequence of a higher
and faster accumulation of ROS in response to hypoxia in
excitable cells. It would be interesting to investigate in future
experiments whether the ROS-dependent hypoxic regulation
of the G6PD gene reported here occurs in other O2-sensitive
tissues and thus represents a more general adaptive mechanism
to ﬁght against oxidative damage in excitable cells.Acknowledgements: We thank Dr. Jose M. Bautista for his help in
setting up G6PD activity assay, Dr. E. Alvarez for the synthesis of
DMOG, and Drs. Antonio G. Castellano, Juan Jose Toledo-Aral and
Raquel del Toro for their helpful advice. This project was supported by
grants ‘‘Ayuda a la Investigacion 2000’’ of the Juan March Founda-
tion and the 2003 Lilly Foundation award to Dr. J. Lopez-Barneo.
L.G. received postdoctoral fellowships of the NSF-NATO and the
Spanish Ministry of Education. R.M. was supported by a predoctoral
fellowship from the Spanish Ministry of Education.References
[1] Semenza, G.L. (2000) J. Appl. Physiol. 88, 1474–1480.
[2] Minchenko, O., Opentanova, I. and Caro, J. (2003) FEBS Lett.
554, 264–270.
[3] Semenza, G.L., Roth, P.H., Fang, H.M. and Wang, G.L. (1994) J.
Biol. Chem. 269, 23757–23763.
[4] Semenza, G.L. (2001) Curr. Opin. Cell Biol. 13, 167–171.
[5] Chandel, N.S. and Schumacker, P.T. (2000) J. Appl. Physiol. 88,
1880–1889.
[6] Jaakkola, P. et al. (2001) Science 292, 468–472.
[7] Ivan, M. et al. (2001) Science 292, 464–468.
[8] Filosa, S. et al. (2003) Biochem. J. 370, 935–943.
[9] Felix, K., Rockwood, L.D., Pretsch, W., Nair, J., Bartsch, H.,
Bornkamm, G.W. and Janz, S. (2002) Free Radic. Biol. Med. 32,
663–673.
[10] Tian, W.N., Braunstein, L.D., Apse, K., Pang, J., Rose, M., Tian,
X. and Stanton, R.C. (1999) Am. J. Physiol. 276, C1121–C1131.
[11] Salvemini, F., Franze, A., Iervolino, A., Filosa, S., Salzano, S. and
Ursini, M.V. (1999) J. Biol. Chem. 274, 2750–2757.
[12] Garcia-Nogales, P., Almeida, A. and Bolanos, J.P. (2003) J. Biol.
Chem. 278, 864–874.
[13] Ursini, M.V., Parrella, A., Rosa, G., Salzano, S. and Martini, G.
(1997) Biochem. J. 323, 801–806.
[14] Lushchak, V.I., Lushchak, L.P., Mota, A.A. and Hermes-Lima,
M. (2001) Am. J. Physiol. Regul. Integr. Comp. Physiol. 280,
R100–R107.
[15] Irlbeck, M., Iwai, T., Lerner, T. and Zimmer, H.G. (1997) J. Mol.
Cell Cardiol. 29, 2931–2939.
[16] LeGrand, T.S. and Aw, T.Y. (1996) Am. J. Physiol. 270, G725–
G729.
[17] Russell, W.J., Ho, Y.S., Parish, G. and Jackson, R.M. (1995) Am.
J. Physiol. 269, L221–L226.
[18] Shan, X., Aw, T.Y., Smith, E.R., Ingelman-Sundberg, M.,
Mannervik, B., Iyanagi, T. and Jones, D.P. (1992) Biochem.
Pharmacol. 43, 2421–2426.
[19] Czyzyk-Krzeska, M.F., Furnari, B.A., Lawson, E.E. and Mill-
horn, D.E. (1994) J. Biol. Chem. 269, 760–764.
[20] Zhu, W.H., Conforti, L., Czyzyk-Krzeska, M.F. and Millhorn,
D.E. (1996) Am. J. Physiol. 271, C658–C665.
[21] Yuan, Y., Hilliard, G., Ferguson, T. and Millhorn, D.E. (2003) J.
Biol. Chem. 278, 15911–15916.
[22] Bautista, J.M., Mason, P.J. and Luzzatto, L. (1992) Biochim.
Biophys. Acta 1119, 74–80.
[23] Cathala, G., Savouret, J.F., Mendez, B., West, B.L., Karin, M.,
Martial, J.A. and Baxter, J.D. (1983) DNA 2, 329–335.
[24] Del Toro, R., Levitsky, K.L., Lopez-Barneo, J. and Chiara, M.D.
(2003) J. Biol. Chem. 278, 22316–22324.
[25] Vaux, E.C., Metzen, E., Yeates, K.M. and Ratcliﬀe, P.J. (2001)
Blood 98, 296–302.
[26] Chandel, N.S., Maltepe, E., Goldwasser, E., Mathieu, C.E.,
Simon, M.C. and Schumacker, P.T. (1998) Proc. Natl. Acad. Sci.
USA 95, 11715–11720.
[27] Chandel, N.S., McClintock, D.S., Feliciano, C.E., Wood, T.M.,
Melendez, J.A., Rodriguez, A.M. and Schumacker, P.T. (2000) J.
Biol. Chem. 275, 25130–25138.
[28] Semenza, G.L. (1999) Annu. Rev. Cell. Dev. Biol. 15, 551–578.
[29] Agani, F.H., Pichiule, P., Chavez, J.C. and LaManna, J.C. (2000)
J. Biol. Chem. 275, 35863–35867.
[30] Haddad, J.J., Olver, R.E. and Land, S.C. (2000) J. Biol. Chem.
275, 21130–21139.
[31] Tacchini, L., Fusar-Poli, D. and Bernelli-Zazzera, A. (2002)
Biochem. Pharmacol. 63, 139–148.
[32] Duyndam, M.C., Hulscher, T.M., Fontijn, D., Pinedo, H.M. and
Boven, E. (2001) J. Biol. Chem. 276, 48066–48076.
[33] Yoshimura, S., Banno, Y., Nakashima, S., Hayashi, K., Yamak-
awa, H., Sawada, M., Sakai, N. and Nozawa, Y. (1999) J.
Neurochem. 73, 675–683.
[34] Fandrey, J., Frede, S. and Jelkmann, W. (1994) Biochem. J. 303,
507–510.
[35] Wenger, R.H. and Gassmann, M. (1997) Biol. Chem. 378,
609–616.
[36] Halliwell, B. and Gutteridge, J.M. (1990) Methods Enzymol. 186,
1–85.
